TIBAUT, Miha, Martin CAPRNDA, Peter KUBATKA, Andreja SINKOVIC, Vanda VALENTOVA, Slavomira FILIPOVA, Katarina GAZDIKOVA, Ludovit GASPAR, Ioana MOZOS, Emmanuel E. EGOM, Luis RODRIGO, Peter KRUŽLIAK and Daniel PETROVIC. Markers of Atherosclerosis. Part 2, Genetic and Imaging Markers. HEART LUNG AND CIRCULATION. NEW YORK: ELSEVIER SCIENCE INC, 2019, vol. 28, No 5, p. 678-689. ISSN 1443-9506. Available from: https://dx.doi.org/10.1016/j.hlc.2018.09.006.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Markers of Atherosclerosis. Part 2, Genetic and Imaging Markers
Authors TIBAUT, Miha (705 Slovenia), Martin CAPRNDA (703 Slovakia), Peter KUBATKA (703 Slovakia), Andreja SINKOVIC (705 Slovenia), Vanda VALENTOVA (703 Slovakia), Slavomira FILIPOVA (703 Slovakia), Katarina GAZDIKOVA (703 Slovakia), Ludovit GASPAR (703 Slovakia), Ioana MOZOS (642 Romania), Emmanuel E. EGOM (124 Canada), Luis RODRIGO (724 Spain), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and Daniel PETROVIC (705 Slovenia).
Edition HEART LUNG AND CIRCULATION, NEW YORK, ELSEVIER SCIENCE INC, 2019, 1443-9506.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.194
RIV identification code RIV/00216224:14110/19:00108496
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.hlc.2018.09.006
UT WoS 000462780100008
Keywords in English Biomarkers; Atherosclerosis; Genetic polymorphism; Imaging biomarkers; Carotid intima media thickness; Micro RNA
Tags 14110121, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 16/7/2019 16:15.
Abstract
This is Part 2 of a two-part review summarising current knowledge on biomarkers of atherosclerosis. Part 1 addressed serological biomarkers. Here, in part 2 we address genetic and imaging markers, and other developments in predicting risk. Further improvements in risk stratification are expected with the addition of genetic risk scores. In addition to single nucleotide polymorphisms (SNPs), recent advances in epigenetics offer DNA methylation profiles, histone chemical modifications, and micro-RNAs as other promising indicators of atherosclerosis. Imaging biomarkers are better studied and already have a higher degree of clinical applicability in cardiovascular (CV) event prediction and detection of preclinical atherosclerosis. With new methodologies, such as proteomics and metabolomics, discoveries of new clinically applicable biomarkers are expected.
Links
NV17-29701A, research and development projectName: Ischémií modifikovaný albumin a cirkulující mikroRNA jako nové technologie k monitorování tkáňové ischémie po cévních rekonstrukcích na břišní aortě
PrintDisplayed: 15/10/2024 16:30